BNN BRAIN Biotech AG

2.753USD2.510 EUR · XETRA+2.03%Mkt Cap: 60.15M USDP/E: —

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubato…

Key Statistics

Company
Market Cap60.15M USD
Enterprise Value59.11M USD
Revenue (TTM)50.54M USD
Gross Profit31.41M USD
Net Income (TTM)-12.88M USD
Revenue/Share2.31 USD
Last Price2.753 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees280
CountryDE
SectorBasic Materials
IndustrySpecialty Chemicals
ISINDE0005203947
Valuation
P/E (Trailing)—
P/E (Forward)-6.28
PEG—
EV/EBITDA-10.48
EV/Revenue1.17
P/S1.19
P/B-7.70
EPS (TTM)-0.70 USD
EPS (Forward)-0.44 USD
52W Range
2.33624% of range4.102
52W High4.102 USD
52W Low2.336 USD
Profitability
Gross Margin57.26%
Oper. Margin-18.32%
EBITDA Margin-11.17%
Profit Margin-23.48%
ROE-637.81%
ROA-17.70%
ROIC-182.28%
ROCE-15.28%
Growth
Revenue Growth-16.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.13M USD
CapEx (TTM)1.76M USD
FCF Margin-0.85%
FCF Yield-0.71%
Net Debt-1.03M USD
Net Debt/EBITDA0.18
Net Debt/FCF—
Balance Sheet
Debt/Equity4.64
Current Ratio1.34
Quick Ratio0.06
Book Value/Sh-0.36 USD
Cash/Share0.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.307 USD
Upside (mean)+129.1%
Target Range5.484 USD – 7.129 USD
5.484+129.1% to mean7.129
# Analysts2
Ownership
Shares Out.21.85M
Float9.09M
Insiders58.40%
Institutions8.48%
Technical
SMA 503.005 (-8.4%)
SMA 2002.985 (-7.8%)
Beta0.60
S&P 52W Chg12.00%
Avg Vol (30d)4.96K
Avg Vol (10d)2.31K
Technical Indicators
RSI (14)40.4
MACD-0.0664
MACD Signal-0.0509
MACD Hist.-0.0155
BB Upper3.109 USD
BB Middle2.892 USD
BB Lower2.674 USD
BB Width15.06%
ATR (14)0.1630 USD
Vol Ratio (20d)0.19x

About BRAIN Biotech (ETR: BNN)

›

BRAIN Biotech (ETR: BNN) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 280 employees.

The shares were at 2.510 EUR on 19 November 2026, down 11.0% over 52 weeks. Its 52-week range is 2.130 EUR to 3.740 EUR: the price is 32.9% below the high and 17.8% above the low.

Its market capitalisation is 54.84M EUR.

BRAIN Biotech reports an operating margin of -18.3% and revenue down 16.5% year over year.

It holds more cash than debt, a net cash position of 940.00K EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 5.750 EUR is 129.1% above the current price.